Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Debates The “Slowdown”: Temple Sees No Sign Of Excess Caution

Executive Summary

An analysis of recent drug approvals that took longer than one year shows no indications of a more conservative attitude by FDA, Office of Medical Policy Director Robert Temple, MD, told the Food & Drug Law Institute conference April 17 in Washington, D.C

You may also be interested in...



NME Approval Decline Likely To Continue In 2002: Only Two Filed This Year

FDA has received only two NDAs for new molecular entities so far in 2002, Office of New Drugs Director John Jenkins, MD, told UBS Warburg's specialty pharma conference in New York City June 6

NME Approval Decline Likely To Continue In 2002: Only Two Filed This Year

FDA has received only two NDAs for new molecular entities so far in 2002, Office of New Drugs Director John Jenkins, MD, told UBS Warburg's specialty pharma conference in New York City June 6

FDA Restricted Distribution Rulemaking May Clarify Regulatory Issues

FDA may consider a formal rulemaking on the use of restricted distribution programs

Related Content

UsernamePublicRestriction

Register

PS039699

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel